Analystreport

Rubius Therapeutics Inc (NASDAQ: RUBY) is now covered by analysts at Leerink Swann. They set an "outperform" rating on the stock.

Rubius Therapeutics, Inc.  (RUBY) 
Last rubius therapeutics, inc. earnings: 3/12 07:00 am Check Earnings Report